New RA drug LFD-200 enters early human safety trials

NCT ID NCT07207954

Recruiting now Symptom relief Sponsor: Lifordi Immunotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This early-stage study tests a new drug called LFD-200 in healthy volunteers and people with moderate to severe rheumatoid arthritis (RA). The main goal is to see if the drug is safe and how the body processes it. Researchers will give single or multiple doses and watch for side effects. This is a first step to see if LFD-200 might help control RA symptoms in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

"ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials
RECRUITING

Kyiv, 1135, Ukraine
Arensia Exploratory Medicine LLC
RECRUITING

Tbilisi, 112, Georgia
Centrum Medyczne Reuma Park
NOT_YET_RECRUITING

Warsaw, 02-691, Poland
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M.
RECRUITING

Chisinau, MD2025, Moldova
MICS Centrum Medyczne Torun - MICS - PPDS
NOT_YET_RECRUITING

Torun, 87-100, Poland
Nucleus Network
RECRUITING

Melbourne, 3004, Australia

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS